OUR SCIENCE

NeuroPro discovers new therapies to treat neurological disorders

What makes NeuroPro Therapeutics technology needed today?

There are indications that our drug candidates will provide better control of seizures without serious side effects common to most anti-epileptic drugs, even in patients who cannot control their seizures with currently available ASMs.

Learn more

patient design element for biotech website

for patients

stethoscope design element for biotech website

for providers

Relevant publications

Epilepsy

Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy. CNS Drugs. 2019 Mar;33(3):283-291. doi:10.1007/s40263-019-00607-5
Eftekhari S, Habibabadi JM, Ziarani MN, Fesharaki SSH, Gharakhani M, Mostafavi H, Joghataei MT, Beladimoghadam N, Rahimian E, Hadjighassem MR. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013 Jan;54(1):e9-12. doi:10.1111/j.1528-1167.2012.03654.x
Hochman DW. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia. 2012 Jun;53(suppl 1):18-25. doi:10.1111/j.1528-1167.2012.03471.x
Haglund MM, Hochman DW. Furosemide and mannitol suppression of epileptic activity in the human brain. J Neurophysiol. 2005 Aug;94(2):907-918. doi:10.1152/jn.00944.2004
No more Publications to show

Anxiety

Krystal AD, Sutherland J, Hochman DW. Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. PLoS One. 2012;7(4):e35417. doi:10.1371/journal.pone.0035417

Migraine

Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology. 2000 Sep 12;55(5):732-733. doi:10.1212/wnl.55.5.732
Read SJ, Smith MI, Benham CD, Hunter AJ, Parsons AA. Furosemide inhibits regenerative cortical spreading depression in anaesthetized cats. Cephalalgia. 1997 Dec;17(8):826-832. doi:10.1046/j.1468-2982.1997.1708826.x

Alzheimers

Taubes A, Nova P, Zalocusky KA, Kosti I, Bicak M, Zilberter MY, Hao Y, Yoon SY, Oskotsky T, Pineda S, Chen B, Jones EAA, Choudhary K, Grone B, Balestra ME, Chaudhry F, Paranjpe I, De Freitas J, Koutsodendris N, Chen N, Wang C, Chang W, An A, Glicksberg BS, Sirota M, Huang Y. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease. Nat Aging. 2021 Oct;1(10):932-947. doi:10.1038/s43587-021-00122-7

Neuropathic pain

Nasirinezhad F, Zarepour L, Hadjighassem M, Gharaylou Z, Majedi H, Ramezani F. Analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury. Basic Clin Neurosci. 2021;12(3):409-420. doi:10.32598/bcn.12.3.2049.1

Contact us to learn more about NeuroPro's drug development portfolio.